Abstract
MicroRNAs (miRNAs) are emerging as important regulators in various pathobiological processes in cancer. Genistein, as a major isoflavonoid isolated from dietary soybean, possesses a wide variety of biological activities particularly in cancer prevention. However, the molecular mechanisms by which genistein elicits its effects on ovarian cancer cells have not been fully elucidated. In this study, we reported that expression of miR-27a was higher in human ovarian cancer relative to benign ovarian tissues. Meanwhile, transfection of SKOV3 cells with the inhibitor of miR-27a suppressed growth and migration of tumor cells. Our study also found that treatment of ovarian cancer cells with genistein caused an inhibition of ovarian cancer cell growth and migration. Further cellular mechanistic studies revealed that genistein down-regulated miR-27a expression, which was accompanied by significantly increased expression of Sprouty2, a putative miR-27a target gene. Taken together, our findings reveal that oncogenic miR-27a plays an important role in ovarian cancer cell growth and metastasis, and genistein, as nontoxic inactivators of miRNA, can block ovarian cancer cell growth and migration, offering novel insights into the mechanisms of genistein therapeutic actions.
Keywords: Genistein, Ovarian cancer, microRNA-27a (miR-27a), Target gene, Sprouty2, SKOV3.
Anti-Cancer Agents in Medicinal Chemistry
Title:Oncogenic MicroRNA-27a is a Target for Genistein in Ovarian Cancer Cells
Volume: 13 Issue: 7
Author(s): Linlin Xu, Jingying Xiang, Jian Shen, Xi Zou, Sulan Zhai, Yongxiang Yin, Ping Li, Xuerong Wang and Qingmin Sun
Affiliation:
Keywords: Genistein, Ovarian cancer, microRNA-27a (miR-27a), Target gene, Sprouty2, SKOV3.
Abstract: MicroRNAs (miRNAs) are emerging as important regulators in various pathobiological processes in cancer. Genistein, as a major isoflavonoid isolated from dietary soybean, possesses a wide variety of biological activities particularly in cancer prevention. However, the molecular mechanisms by which genistein elicits its effects on ovarian cancer cells have not been fully elucidated. In this study, we reported that expression of miR-27a was higher in human ovarian cancer relative to benign ovarian tissues. Meanwhile, transfection of SKOV3 cells with the inhibitor of miR-27a suppressed growth and migration of tumor cells. Our study also found that treatment of ovarian cancer cells with genistein caused an inhibition of ovarian cancer cell growth and migration. Further cellular mechanistic studies revealed that genistein down-regulated miR-27a expression, which was accompanied by significantly increased expression of Sprouty2, a putative miR-27a target gene. Taken together, our findings reveal that oncogenic miR-27a plays an important role in ovarian cancer cell growth and metastasis, and genistein, as nontoxic inactivators of miRNA, can block ovarian cancer cell growth and migration, offering novel insights into the mechanisms of genistein therapeutic actions.
Export Options
About this article
Cite this article as:
Xu Linlin, Xiang Jingying, Shen Jian, Zou Xi, Zhai Sulan, Yin Yongxiang, Li Ping, Wang Xuerong and Sun Qingmin, Oncogenic MicroRNA-27a is a Target for Genistein in Ovarian Cancer Cells, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (7) . https://dx.doi.org/10.2174/18715206113139990006
DOI https://dx.doi.org/10.2174/18715206113139990006 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
Clinical Cancer Drugs The Wnt Pathway: Emerging Anticancer Strategies
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry ERK Signaling Pathway Regulates Embryonic Survival and Eye Development in Goldfish, Carassius auratus
Current Molecular Medicine Pharmacoepigenomics: An Interplay of Epigenetic Modulation of Drug Response and Modulation of the Epigenome by Drugs
Current Pharmaceutical Design Targeted Nanosystems for Cancer Therapy
Current Cancer Therapy Reviews Combination of Photodynamic Therapy with Anti-Cancer Agents
Current Medicinal Chemistry Fibroblast Growth Factors in Development and Cancer: Insights from the Mammary and Prostate Glands
Current Drug Targets Cell-based Assays for Assessing Toxicity: A Basic Guide
Medicinal Chemistry Meet Our Editorial Board Member:
Current Pharmaceutical Design Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets Acyl Thiourea Derivatives Containing Pyrazole Ring Selective Targeting of Human Aurora Kinases in Breast and Bone Cancer
Letters in Drug Design & Discovery Berberine Interfered with Breast Cancer Cells Metabolism, Balancing Energy Homeostasis
Anti-Cancer Agents in Medicinal Chemistry Role of Flavonoids in Future Anticancer Therapy by Eliminating the Cancer Stem Cells
Current Stem Cell Research & Therapy Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets Idronoxil as an Anticancer Agent: Activity and Mechanisms
Current Cancer Drug Targets Recent Advances, Issues and Patents on Medical Nanorobots
Recent Patents on Engineering Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Signal Transduction and Heavy Ion Radiation Therapy: Biological Mechanisms, Biological Quality Assurance, and New Multimodality Approach
Current Signal Transduction Therapy Organ Preference of Cancer Metastasis and Metastasis-Related Cell Adhesion Molecules Including Carbohydrates
Cardiovascular & Hematological Disorders-Drug Targets